Lipid System Articles & Analysis
6 news found
HM King Philippe and HM Queen Mathilde, currently on a state visit to South Africa until March 27, visited the Afrigen Biologics facility in Cape Town to learn more about how two Belgian companies, Univercells and etherna, are supporting the development of the first African- developed mRNA COVID-19 vaccine. The King and The Queen are accompanied by five ministers of federal and regional ...
ByeTheRNA
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, has now expanded lipid system portfolio and launched a series of Sphingolipids products to support customers' scientific research. CD Bioparticles now offers more choices for researchers to choose from and use in lipid system applications, such as Ceramides, Sphingosines, Sphingomyelin, ...
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, now introduces a series of prostaglandins products to support drug delivery related research. These new products offer comprehensive choices for researchers, such as Prostaglandin F2a (11beta epimer), Prostaglandin A1, Prostaglandin F1ß, Prostaglandin E2, and Prostaglandin E1-d9. CD ...
The founders of Acuitas Therapeutics, Drs. Pieter Cullis, Michael Hope and Thomas Madden, have been named as Governor General’s Innovation Award recipients. This prestigious award is for their work in developing lipid nanoparticle (LNP) systems to deliver cancer drugs to tumours and to enable RNA- and DNA-based drugs to be used therapeutically. Among other achievements, their work has ...
As a New York-based CRO company, CD Formulation has keenly observed that the demand for tailored pharmaceutical excipients is on the rise, especially over the past decade, as each formulation project may need unique excipients. In response to such a market trend, the management of CD Formulation earlier this month announces to offer customized synthesis for lipid excipients, which are used in ...
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems ...